** Shares of cancer drugmaker Verastem VSTM.O rise 45.7% to $5.35 premarket
** On Monday, VSTM said the U.S. FDA granted Priority Review to its application for its experimental cancer therapy, avutometinib in combination with defactinib
** Drugmaker sought approval for the combo therapy for patients with recurrent low-grade serous ovarian cancer who have a KRAS gene mutation and have received at least one prior systemic therapy
** Priority Review designation means FDA's goal is to take action on an application within 6 months, compared to 10 months under standard review
** Analysts at BTIG say total addressable market for the condition is over $1.7 bln, based on around 2,800 patients in the first 3 to 5 years
** Brokerage also has increased the probability of success for the treatment from 65% to 80%, raising PT from $13 to $20, representing a 5x upside to the stock's Monday close
** Brokerage B. Riley Securities notes VSTM is "fundamentally undervalued"
** The FDA will give its decision on June 30, 2025 - VSTM
** FDA is not currently planning to hold an advisory committee meeting to discuss the application - VSTM
** Co said it is preparing for commercial launch in mid-2025
** As of last close, stock has fallen ~55% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.